What is Zacks Research’s Forecast for TEVA Q3 Earnings?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Stock analysts at Zacks Research boosted their Q3 2025 earnings per share estimates for shares of Teva Pharmaceutical Industries in a research note issued to investors on Monday, November 4th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.67 for the quarter, up from their prior forecast of $0.66. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.33 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ FY2025 earnings at $2.55 EPS and Q2 2026 earnings at $0.61 EPS.

Several other equities analysts have also recently commented on the stock. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Barclays upped their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Wednesday, July 10th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Stock Down 7.1 %

TEVA stock opened at $17.43 on Wednesday. The company has a market cap of $19.75 billion, a PE ratio of -44.69, a price-to-earnings-growth ratio of 1.34 and a beta of 0.87. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. Teva Pharmaceutical Industries has a 52 week low of $8.55 and a 52 week high of $19.31. The business has a 50-day simple moving average of $18.00 and a 200 day simple moving average of $17.06.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Hedge funds have recently added to or reduced their stakes in the business. New Covenant Trust Company N.A. bought a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at $28,000. EntryPoint Capital LLC acquired a new position in Teva Pharmaceutical Industries during the 1st quarter worth about $30,000. UMB Bank n.a. grew its position in shares of Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after buying an additional 2,067 shares during the last quarter. Claro Advisors LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $52,000. Finally, Beach Investment Counsel Inc. PA acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at about $48,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.